

06/11/04

1626

slw



Express Mail No.: EV 475 140 515 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bennett et al.

Confirmation No.: 6892

Application No.: 09/642,557

Group Art Unit: 1626

Filed: August 18, 2000

Examiner: Wright, S.

For: PYRAZOLOANTHRONE AND
DERIVATIVES THEREOF AS
JNK INHIBITORS AND
COMPOSITIONS AND
METHODS RELATED THERETO

Attorney Docket No.: 10624-046-999Z
CAM: 700755-999045

STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. § 1.133

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attorneys for Applicant thank Examiner Wright for extending the courtesy of a telephonic interview on May 12, 2004 in connection with the above-identified application.

Pursuant to 37 C.F.R. § 1.133 and M.P.E.P. 713.04, Attorneys for Applicant submit this Statement of Substance of Interview in connection with the telephonic interview of May 12, 2004 between Examiner Sonya Wright and Attorneys for Applicant Anthony M. Insogna and Michael J. Bruner in connection with the above-identified application.

Examiner Wright agreed to reconsider the outstanding rejection under 35 U.S.C. § 102(b) over STN International CAPLUS Database, Accession No. 1989:1851777 to Showalter *et al.* ("Showalter Abstract"). Attorneys for Applicant explained why the rejected claims are not anticipated by the cited art regardless of whether or not the Showalter Abstract discloses the compound anthra[1,9-cd]pyrazol-6(2H)-one. In addition, Applicant briefly referred to the evidence of record from Chemical Abstracts Services ("CAS") which rebuts

the Examiner's interpretation of the Showalter Abstract. The Examiner agreed to reconsider the remarks and amendments set forth in the Reply to Final Office Action Under 37 C.F.R. § 1.113 filed in the United States Patent and Trademark Office ("USPTO") on March 15, 2004 in connection with the above-identified application and the letter from CAS submitted concurrently therewith.

Attorneys for Applicant submitted a Supplemental Reply to Final Office Action Under 37 C.F.R. § 1.113 concurrently with a Request for Continued Examination Under 37 C.F.R. § 1.114 in the USPTO on May 13, 2004 in connection with the above-identified application in order for the Examiner to reconsider the rejection under 35 U.S.C. § 102(b).

Attorneys for Applicant respectfully request entry of the foregoing remarks into the file history of the above-identified application. It is believed that no fee is due in connection with this Statement; however, in the event any fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

Date: June 9, 2004

By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)
For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130